Clinical Trial: The Efficacy of Combined Peripheral Blood CTCs and Serum HER2 Detection in Docetaxel-based Treatment for HER2 Low-expression Breast Cancer

U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07670182) titled 'The Efficacy of Combined Peripheral Blood CTCs and Serum HER2 Detection in Docetaxel-based Treatment for HER2 Low-expression Breast Cancer' on June 08.

Brief Summary: This study is a multicenter, double-cohort clinical research aimed at systematically evaluating the value of jointly detecting the HER2 expression of CTCs/CTECs and the serum HER2 ECD level in predicting the efficacy of T-DXd treatment for patients with HER2 low expression (IHC 1+ or IHC 2+/ISH-) and HER2 IHC 0 advanced breast cancer.

Study Start Date: June 15

Study Type: OBSERVATIONAL

Condition: Patients With Low HER2 Expression (IHC 1+ or IHC 2+/ISH-) and HER2 IH...